Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Mar 18, 2026 · 10-K · 77 days after period end · 0001493152-26-011204
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$3.36M | -$2.73M | -$2.40M | -$13.01M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 18, 2026 · 77 d after period end
